GLP-1/GIP candidate VK2735 shows reductions in subjects' liver fat content and plasma lipid levelsOutcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment3 days ago